Online Inquiry

Global Services. (Creative Biolabs Authorized)

Cross-Platform Delivery System Integration Benchmarking Service

Online Inquiry

Background Service What We Can Offer Workflow Highlights FAQs Contact

Current challenges in cell therapy development include inconsistent integration efficiency, uncontrolled transgene expression, and genotoxicity risks across diverse delivery systems for CAR-T applications. Our Cross-Platform Delivery System Integration Benchmarking Services provide standardized, head‑to‑head comparisons of integration frequency across lentivirus, retrovirus, AAV, and non‑viral transposon systems. Our service delivers quantitative benchmarks and risk profiles tailored to early‑stage vector screening. By enabling rational backbone design and mitigating clonal expansion hazards, it accelerates identification of safe, high‑performance delivery platforms for CAR-T therapy.

Introduction

Multiple delivery vectors including lentivirus, retrovirus, AAV, and non‑viral transposon systems are commonly used to stably integrate CAR transgenes into T cells for in vivo therapy. However, each platform presents distinct integration profiles and safety risks, such as insertional mutagenesis, clonal dominance, and genotoxicity, which must be carefully evaluated during early‑stage candidate screening.

Fig.1 Vector constructs and transgene activation. (OA Literature) Fig.1 Gene delivery vehicles and transgene transcription.¹

Our Service

Our Cross-Platform Delivery System Integration Benchmarking Services provide standardized quantification of integration frequency, clonal distribution, and genotoxicity risk across lentivirus, retrovirus, AAV, and non‑viral transposons. This enables data‑driven vector selection for in vivo CAR‑T therapy, accelerating safe and potent candidate screening while mitigating insertional oncogenesis.

What We Can Offer

Our services deliver cross‑platform integration benchmarking, clonality, and safety risks, enabling data‑driven vector selection in CAR‑T therapy.

Featured services of cross-platform delivery system integration benchmarking services at Creative Biolabs. (Creative Biolabs Original)

Our Service Process

Required Starting Materials:

Delivery Vectors: Lentivirus, retrovirus, AAV, or non-viral transposon plasmids (containing the target CAR expression cassette).
Host Cells: Target cell types (e.g., primary human T cells, T cell line Jurkat, or CAR-T production-grade PBMCs).
Controls: Reference cell lines with known integration frequency (e.g., HEK293 stable pools) and untreated negative control cells.

Key Steps:

Workflow of cross-platform delivery system integration benchmarking services at Creative Biolabs. (Creative Biolabs Original)

Final Deliverables

Quantitative Report: Integration copy number per cell, net integration efficiency, percentage of positive cells.
Clonal Mapping: Chromosomal distribution map of integration sites, highly integrated clones.

Key Advantages

Cross-Platform Fair Comparison: We provide the first true head‑to‑head benchmarking of integration frequency across distinct delivery systems using unified internal controls and correction factors.
Prospective Clonal Safety Assessment: We calculate diversity indices and map distances to proto‑oncogenes, enabling early warning of insertional mutagenesis risks before preclinical stages.
Actionable Optimization Guidance: We go beyond data delivery by providing vector backbone design recommendations, such as LTR modifications or transposon terminal repeat adjustments, to support rational platform selection.

FAQ

Q1: Which delivery systems are covered by this service?

A1: We support benchmarking for lentivirus, retrovirus, AAV, and Sleeping Beauty transposon systems. In addition, we can accommodate custom or emerging vector platforms upon request.

Q2: How do you ensure comparable results across different platforms?

A2: To enable fair cross‑platform comparisons, we apply a consistent reference gene, a shared reporter expression cassette, and standardized correction factors. This setup removes methodological biases that would otherwise compromise data alignment.

Q3: Is this service suitable for CAR‑T candidate screening?

A3: Absolutely. Our benchmarking data directly supports early‑stage candidate selection by comparing integration efficiency, clonal safety, and expression stability across delivery platforms. This enables researchers to identify the most appropriate vector for subsequent in vivo applications.

Why Choose Us?

We deliver the only standardized, cross‑platform integration benchmarking for different delivery systems in in vivo CAR‑T development. Our head‑to‑head comparisons, rigorous safety profiling, and actionable vector design guidance empower you to select the safest, most efficient delivery platform with confidence.

Customer Reviews

"We relied on this benchmarking service to evaluate AAV integration frequency for our tissue-specific CAR delivery. The rare-event detection and proto-oncogene proximity mapping gave us the confidence to advance a candidate that was both efficient and clean. I highly recommend their cross-platform approach to any cell therapy group." Dr. M* C*.

"Our team was stuck between retrovirus and non-viral integrating vector for an allogeneic CAR-T project. The integration clonal mapping and Shannon diversity index provided by this service clearly showed which platform minimized insertional risk. Thanks to their actionable recommendations, we moved into in vivo proof-of-concept three months faster than planned." Dr. S* K.

"What stood out most was the unbiased head-to-head comparison across four delivery systems. The final report not only gave us copy numbers per cell but also vector design suggestions that we immediately implemented. This service turned a complex technical decision into a straightforward data-driven choice." Dr. J*.

How to contact us?

Interested in comparing your delivery platforms for safer in vivo CAR‑T candidate selection? Contact our technical team to review your project needs, obtain a tailored quote, or arrange a one‑on‑one consultation. We're eager to help move your screening efforts forward.

Reference

Wang, Nathan B et al. "Engineering cell fate: Applying synthetic biology to cellular reprogramming." Current opinion in systems biology vol. 24 (2020): 18-31. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.1016/j.coisb.2020.09.002.

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.